{"organizations": [], "uuid": "93ade468a406039a565001ec03d6ea18924e0d46", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-kamada-announces-data-from-phase-2/brief-kamada-announces-data-from-phase-2-clinical-trial-of-intravenous-alpha-1-antitrypsin-treatment-for-prevention-of-lung-transplant-rejection-idUSASB0C00Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Kamada Announces Data From Phase 2 Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment For Prevention Of Lung Transplant Rejection", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-01-08T20:10:00.000+02:00", "replies_count": 0, "uuid": "93ade468a406039a565001ec03d6ea18924e0d46"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kamada-announces-data-from-phase-2/brief-kamada-announces-data-from-phase-2-clinical-trial-of-intravenous-alpha-1-antitrypsin-treatment-for-prevention-of-lung-transplant-rejection-idUSASB0C00Z", "ord_in_thread": 0, "title": "BRIEF-Kamada Announces Data From Phase 2 Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment For Prevention Of Lung Transplant Rejection", "locations": [], "entities": {"persons": [{"name": "kamada", "sentiment": "neutral"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "kamada ltd", "sentiment": "neutral"}, {"name": "antitrypsin treatment for prevention of lung transplant rejection jan", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Kamada Ltd:\n* KAMADA ANNOUNCES INTERIM RESULTS FROM PHASE 2 CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION\n* KAMADA LTD - TOP-LINE RESULTS FROM PHASE 2 TRIAL OF ALPHA-1 ANTITRYPSIN ANTICIPATED IN H2 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:10:00.000+02:00", "crawled": "2018-01-09T17:12:09.016+02:00", "highlightTitle": ""}